Literature DB >> 22415987

Derivation of mesenchymal stem cells from human induced pluripotent stem cells cultured on synthetic substrates.

L G Villa-Diaz1, S E Brown, Y Liu, A M Ross, J Lahann, J M Parent, P H Krebsbach.   

Abstract

Human-induced pluripotent stem cells (hiPSCs) may represent an ideal cell source for research and applications in regenerative medicine. However, standard culture conditions that depend on the use of undefined substrates and xenogeneic medium components represent a significant obstacle to clinical translation. Recently, we reported a defined culture system for human embryonic stem cells using a synthetic polymer coating, poly[2-(methacryloyloxy)ethyl dimethyl-(3-sulfopropyl)ammonium hydroxide] (PMEDSAH), in conjunction with xenogeneic-free culture medium. Here, we tested the hypothesis that iPSCs could be maintained in an undifferentiated state in this xeno-free culture system and subsequently be differentiated into mesenchymal stem cells (iPS-MSCs). hiPSCs were cultured on PMEDSAH and differentiated into functional MSCs, as confirmed by expression of characteristic MSC markers (CD166+, CD105+, CD90+,CD73+, CD31-, CD34-, and CD45-) and their ability to differentiate in vitro into adipogenic, chondrogenic, and osteoblastic lineages. To demonstrate the potential of iPS-MSCs to regenerate bone in vivo, the newly derived cells were induced to osteoblast differentiation for 4 days and transplanted into calvaria defects in immunocompromised mice for 8 weeks. MicroCT and histologic analyses demonstrated de novo bone formation in the calvaria defects for animals treated with iPS-MSCs but not for the control group. Moreover, positive staining for human nuclear antigen and human mitochondria monoclonal antibodies confirmed the participation of the transplanted hiPS-MSCs in the regenerated bone. These results demonstrate that hiPSCs cultured in a xeno-free system have the capability to differentiate into functional MSCs with the ability to form bone in vivo.
Copyright © 2012 AlphaMed Press.

Entities:  

Mesh:

Year:  2012        PMID: 22415987      PMCID: PMC3549569          DOI: 10.1002/stem.1084

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  23 in total

1.  Characterization and functionality of cell surface molecules on human mesenchymal stem cells.

Authors:  Manas K Majumdar; Michele Keane-Moore; Diana Buyaner; Wayne B Hardy; Mark A Moorman; Kevin R McIntosh; Joseph D Mosca
Journal:  J Biomed Sci       Date:  2003 Mar-Apr       Impact factor: 8.410

2.  Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement.

Authors:  M Dominici; K Le Blanc; I Mueller; I Slaper-Cortenbach; Fc Marini; Ds Krause; Rj Deans; A Keating; Dj Prockop; Em Horwitz
Journal:  Cytotherapy       Date:  2006       Impact factor: 5.414

3.  Derivation of clinically compliant MSCs from CD105+, CD24- differentiated human ESCs.

Authors:  Qizhou Lian; Elias Lye; Keng Suan Yeo; Eileen Khia Way Tan; Manuel Salto-Tellez; Tong Ming Liu; Nallasivam Palanisamy; Reida Menshawe El Oakley; Eng Hin Lee; Bing Lim; Sai-Kiang Lim
Journal:  Stem Cells       Date:  2006-10-19       Impact factor: 6.277

4.  In vivo osteoprogenitor potency of human stromal cells from different tissues does not correlate with expression of POU5F1 or its pseudogenes.

Authors:  Nikolas Kaltz; Alessia Funari; Sandra Hippauf; Bruno Delorme; Danièle Noël; Mara Riminucci; Volker R Jacobs; Thomas Häupl; Christian Jorgensen; Pierre Charbord; Christian Peschel; Paolo Bianco; Robert A J Oostendorp
Journal:  Stem Cells       Date:  2008-07-10       Impact factor: 6.277

Review 5.  Mesenchymal stromal cell therapy: a revolution in Regenerative Medicine?

Authors:  M E Bernardo; D Pagliara; F Locatelli
Journal:  Bone Marrow Transplant       Date:  2011-04-11       Impact factor: 5.483

6.  Multilineage potential of adult human mesenchymal stem cells.

Authors:  M F Pittenger; A M Mackay; S C Beck; R K Jaiswal; R Douglas; J D Mosca; M A Moorman; D W Simonetti; S Craig; D R Marshak
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

7.  Human feeders support prolonged undifferentiated growth of human inner cell masses and embryonic stem cells.

Authors:  Mark Richards; Chui-Yee Fong; Woon-Khiong Chan; Peng-Cheang Wong; Ariff Bongso
Journal:  Nat Biotechnol       Date:  2002-08-05       Impact factor: 54.908

8.  Embryonic stem cell lines derived from human blastocysts.

Authors:  J A Thomson; J Itskovitz-Eldor; S S Shapiro; M A Waknitz; J J Swiergiel; V S Marshall; J M Jones
Journal:  Science       Date:  1998-11-06       Impact factor: 47.728

9.  Induction of pluripotent stem cells from adult human fibroblasts by defined factors.

Authors:  Kazutoshi Takahashi; Koji Tanabe; Mari Ohnuki; Megumi Narita; Tomoko Ichisaka; Kiichiro Tomoda; Shinya Yamanaka
Journal:  Cell       Date:  2007-11-30       Impact factor: 41.582

Review 10.  Cell and gene therapy using mesenchymal stem cells (MSCs).

Authors:  Keiya Ozawa; Kazuya Sato; Iekuni Oh; Katsutoshi Ozaki; Ryosuke Uchibori; Yoko Obara; Yuji Kikuchi; Takayuki Ito; Takashi Okada; Masashi Urabe; Hiroaki Mizukami; Akihiro Kume
Journal:  J Autoimmun       Date:  2008-01-31       Impact factor: 7.094

View more
  83 in total

1.  Generation of functional mesenchymal stem cells from different induced pluripotent stem cell lines.

Authors:  Kim Hynes; Danijela Menicanin; Krzysztof Mrozik; Stan Gronthos; P Mark Bartold
Journal:  Stem Cells Dev       Date:  2014-02-07       Impact factor: 3.272

2.  Engineering bone tissue substitutes from human induced pluripotent stem cells.

Authors:  Giuseppe Maria de Peppo; Iván Marcos-Campos; David John Kahler; Dana Alsalman; Linshan Shang; Gordana Vunjak-Novakovic; Darja Marolt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-07       Impact factor: 11.205

Review 3.  Substrates for clinical applicability of stem cells.

Authors:  Sanjar Enam; Sha Jin
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

Review 4.  Application of biomaterials to advance induced pluripotent stem cell research and therapy.

Authors:  Zhixiang Tong; Aniruddh Solanki; Allison Hamilos; Oren Levy; Kendall Wen; Xiaolei Yin; Jeffrey M Karp
Journal:  EMBO J       Date:  2015-03-12       Impact factor: 11.598

5.  Metformin induces osteoblastic differentiation of human induced pluripotent stem cell-derived mesenchymal stem cells.

Authors:  Ping Wang; Tao Ma; Dong Guo; Kevin Hu; Yan Shu; Hockin H K Xu; Abraham Schneider
Journal:  J Tissue Eng Regen Med       Date:  2017-08-11       Impact factor: 3.963

Review 6.  Induced pluripotent stem cells as a new getaway for bone tissue engineering: A systematic review.

Authors:  Farshid Bastami; Pantea Nazeman; Hamidreza Moslemi; Maryam Rezai Rad; Kazem Sharifi; Arash Khojasteh
Journal:  Cell Prolif       Date:  2016-12-01       Impact factor: 6.831

Review 7.  From skeletal development to the creation of pluripotent stem cell-derived bone-forming progenitors.

Authors:  Wai Long Tam; Frank P Luyten; Scott J Roberts
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2018-07-05       Impact factor: 6.237

8.  Cell and Material-Specific Phage Display Peptides Increase iPS-MSC Mediated Bone and Vasculature Formation In Vivo.

Authors:  Harsha Ramaraju; David H Kohn
Journal:  Adv Healthc Mater       Date:  2019-03-05       Impact factor: 9.933

9.  Directed differentiation of human induced pluripotent stem cells toward bone and cartilage: in vitro versus in vivo assays.

Authors:  Matthew D Phillips; Sergei A Kuznetsov; Natasha Cherman; Kyeyoon Park; Kevin G Chen; Britney N McClendon; Rebecca S Hamilton; Ronald D G McKay; Josh G Chenoweth; Barbara S Mallon; Pamela G Robey
Journal:  Stem Cells Transl Med       Date:  2014-05-22       Impact factor: 6.940

10.  Induced pluripotent stem cell reprogramming by integration-free Sendai virus vectors from peripheral blood of patients with craniometaphyseal dysplasia.

Authors:  I-Ping Chen; Keiichi Fukuda; Noemi Fusaki; Akihiro Iida; Mamoru Hasegawa; Alexander Lichtler; Ernst J Reichenberger
Journal:  Cell Reprogram       Date:  2013-11-12       Impact factor: 1.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.